<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01935622</url>
  </required_header>
  <id_info>
    <org_study_id>VCU HM14393</org_study_id>
    <nct_id>NCT01935622</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy</brief_title>
  <acronym>DOXY-HF</acronym>
  <official_title>Phase II Study of Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-ischemic cardiomyopathy and heart failure are highly influenced by the presence of
      systemic inflammation.

      Doxycycline is a FDA-approved drug to treat bacterial infections which also shows powerful
      anti-inflammatory effects.

      In this study we plan to determine the effects of Doxycycline in patients with stable heart
      failure and non-ischemic cardiomyopathy on peak of aerobic exercise capacity (peak V02) and
      ventilator efficiency measured with a cardiopulmonary test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study of Safety and Efficacy of Doxycycline in Patients with Non-Ischemic
      Cardiomyopathy Population, we will enroll 24 patients with a clinical diagnosis of heart
      failure and non-ischemic cardiomyopathy (recent imaging study documenting LV ejection
      fraction &lt;50%, and no history of coronary or ischemic heart disease) in a single-center,
      randomized, double-blinded, placebo-controlled clinical trial with allocation 1:1:1 to
      Doxycycline 100 mg twice daily or Doxycycline 20 mg twice daily or Placebo for 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    End of funding
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Aerobic Exercise Capacity</measure>
    <time_frame>14 days</time_frame>
    <description>Interval change in peak VO2 measured at cardiopulmonary test</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Non-ischemic Cardiomyopathy</condition>
  <condition>Systolic Heart Failure (NYHA II-III)</condition>
  <arm_group>
    <arm_group_label>Doxycycline 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline 100 mg twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline 20 mg twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline 1 tablet every 12 hours for 14 days</description>
    <arm_group_label>Doxycycline 100 mg</arm_group_label>
    <arm_group_label>Doxycycline 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo 1 tablet every 12 hours for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-ischemic cardiomyopathy (LVEF&lt;40%)

          -  Heart failure NYHA II-III

        Exclusion Criteria:

          -  Age &lt;18

          -  Recent changes (previous 3 months) in HF maintenance medications (beta-blockers,
             angiotensin converting enzyme [ACE] inhibitors, aldosterone antagonists, vasodilators,
             cardiac glycosides, diuretics)

          -  Hospitalization for worsening HF or acute decompensated HF within the previous 12
             months

          -  History of coronary or ischemic heart disease

          -  Anticipated need for cardiac resynchronization therapy (CRT) or automated-implantable
             cardioverter defibrillator (AICD) or coronary revascularization or cardiac surgery

          -  Angina or electrocardiograph (ECG) changes that limit maximum exertion during
             cardiopulmonary exercise testing

          -  Active infection including chronic infection

          -  Active cancer (or prior diagnosis of cancer within the past 10 years)

          -  Recent (&lt;14 days) use of anti-inflammatory drugs (not including NSAIDs), Chronic
             inflammatory disorder (including but not limited to rheumatoid arthritis, systemic
             lupus erythematosus), malignancy, or any comorbidity limiting survival or ability to
             complete the study

          -  Pregnancy

          -  Inability to give informed consent

          -  Other conditions limiting completion of cardiopulmonary exercise test or completion of
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Abbate, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <results_first_submitted>June 20, 2014</results_first_submitted>
  <results_first_submitted_qc>August 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2014</results_first_posted>
  <last_update_submitted>August 19, 2014</last_update_submitted>
  <last_update_submitted_qc>August 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>non-ischemic cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Doxycycline 100 mg</title>
          <description>Doxycycline 100 mg twice daily for 14 days
Doxycycline</description>
        </group>
        <group group_id="P2">
          <title>Doxycycline 20 mg</title>
          <description>Doxycycline 20 mg twice daily for 14 days
Doxycycline</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>(No data analysis conducted. Insufficient enrollment)</population>
      <group_list>
        <group group_id="B1">
          <title>Doxycycline 100 mg</title>
          <description>Doxycycline 100 mg twice daily for 14 days
Doxycycline</description>
        </group>
        <group group_id="B2">
          <title>Doxycycline 20 mg</title>
          <description>Doxycycline 20 mg twice daily for 14 days
Doxycycline</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo
placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="48" upper_limit="55"/>
                    <measurement group_id="B2" value="58" lower_limit="55" upper_limit="59"/>
                    <measurement group_id="B3" value="54" lower_limit="49" upper_limit="60"/>
                    <measurement group_id="B4" value="54" lower_limit="48" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Aerobic Exercise Capacity</title>
        <description>Interval change in peak VO2 measured at cardiopulmonary test</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline 100 mg</title>
            <description>Doxycycline 100 mg twice daily for 14 days
Doxycycline</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline 20 mg</title>
            <description>Doxycycline 20 mg twice daily for 14 days
Doxycycline</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Aerobic Exercise Capacity</title>
          <description>Interval change in peak VO2 measured at cardiopulmonary test</description>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">(No data analysis conducted. Insufficient enrollment)</measurement>
                    <measurement group_id="O2" value="NA">(No data analysis conducted. Insufficient enrollment)</measurement>
                    <measurement group_id="O3" value="NA">(No data analysis conducted. Insufficient enrollment)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Doxycycline 100 mg</title>
          <description>Doxycycline 100 mg twice daily for 14 days
Doxycycline</description>
        </group>
        <group group_id="E2">
          <title>Doxycycline 20 mg</title>
          <description>Doxycycline 20 mg twice daily for 14 days
Doxycycline</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>(No data analysis conducted. Insufficient enrollment)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Antonio Abbate</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>8048280513</phone>
      <email>aabbate@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

